Cargando…

Systane(®) lubricant eye drops in the management of ocular dryness

The understanding of dry eye disease has advanced recently through increasing recognition that the etiology of the condition involves both tear evaporation and insufficient tear production, and that tear film instability and inflammation play roles in the various stages of the disease. Of significan...

Descripción completa

Detalles Bibliográficos
Autor principal: Benelli, Umberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130915/
https://www.ncbi.nlm.nih.gov/pubmed/21750611
http://dx.doi.org/10.2147/OPTH.S13773
_version_ 1782207665914511360
author Benelli, Umberto
author_facet Benelli, Umberto
author_sort Benelli, Umberto
collection PubMed
description The understanding of dry eye disease has advanced recently through increasing recognition that the etiology of the condition involves both tear evaporation and insufficient tear production, and that tear film instability and inflammation play roles in the various stages of the disease. Of significance, it has been recognized that lipid layer thickness correlates with tear film stability. The management of dry eye involves various strategies and therapeutic approaches that address one or more etiopathological components of the disease. The purpose of this review is to outline the characteristics and clinical utility of the Systane(®) ocular lubricants that contain hydroxypropyl-guar and one or both of the demulcents, ie, polyethylene glycol 400 and propylene glycol. Clinically, these products are safe and are indicated for the temporary relief of burning and irritation due to dryness of the eye. In particular, this review describes the formulations, mechanisms of action, and clinical utility of the newest additions to this topical ocular lubricant family, Systane Ultra(®) and Systane Balance(®). Both of these ocular products are formulated with an intelligent delivery system and both provide symptomatic relief to patients with dry eye. However, Systane Balance is a novel formulation that contains both polymer and lipid components designed to protect the ocular surface and replenish tear film lipids simultaneously, a factor that is of particular relevance to patients who have dry eye associated with meibomian gland dysfunction.
format Online
Article
Text
id pubmed-3130915
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31309152011-07-12 Systane(®) lubricant eye drops in the management of ocular dryness Benelli, Umberto Clin Ophthalmol Review The understanding of dry eye disease has advanced recently through increasing recognition that the etiology of the condition involves both tear evaporation and insufficient tear production, and that tear film instability and inflammation play roles in the various stages of the disease. Of significance, it has been recognized that lipid layer thickness correlates with tear film stability. The management of dry eye involves various strategies and therapeutic approaches that address one or more etiopathological components of the disease. The purpose of this review is to outline the characteristics and clinical utility of the Systane(®) ocular lubricants that contain hydroxypropyl-guar and one or both of the demulcents, ie, polyethylene glycol 400 and propylene glycol. Clinically, these products are safe and are indicated for the temporary relief of burning and irritation due to dryness of the eye. In particular, this review describes the formulations, mechanisms of action, and clinical utility of the newest additions to this topical ocular lubricant family, Systane Ultra(®) and Systane Balance(®). Both of these ocular products are formulated with an intelligent delivery system and both provide symptomatic relief to patients with dry eye. However, Systane Balance is a novel formulation that contains both polymer and lipid components designed to protect the ocular surface and replenish tear film lipids simultaneously, a factor that is of particular relevance to patients who have dry eye associated with meibomian gland dysfunction. Dove Medical Press 2011 2011-06-10 /pmc/articles/PMC3130915/ /pubmed/21750611 http://dx.doi.org/10.2147/OPTH.S13773 Text en © 2011 Benelli, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Benelli, Umberto
Systane(®) lubricant eye drops in the management of ocular dryness
title Systane(®) lubricant eye drops in the management of ocular dryness
title_full Systane(®) lubricant eye drops in the management of ocular dryness
title_fullStr Systane(®) lubricant eye drops in the management of ocular dryness
title_full_unstemmed Systane(®) lubricant eye drops in the management of ocular dryness
title_short Systane(®) lubricant eye drops in the management of ocular dryness
title_sort systane(®) lubricant eye drops in the management of ocular dryness
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130915/
https://www.ncbi.nlm.nih.gov/pubmed/21750611
http://dx.doi.org/10.2147/OPTH.S13773
work_keys_str_mv AT benelliumberto systanelubricanteyedropsinthemanagementofoculardryness